A
Aseptuva develops Far‑UVC disinfection solutions that prevent bacterial colonization and biofilm formation on catheter entry sites, reducing the risk of hospital‑acquired bloodstream infections. By integrating continuous UV treatment into catheter care, the technology shortens ICU length of stay, cuts associated costs, and lessens the workload for healthcare staff. The approach also offers a non‑antibiotic method to combat antimicrobial resistance in clinical settings.
Winterthur, SwitzerlandFounded 2021
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- Aseptuva develops Far‑UVC disinfection solutions that inhibit bacterial colonization on catheter entry sites, reducing the risk of hospital‑acquired infections. Their technology prevents biofilm formation and bloodstream infections, lowering ICU length of stay and associated treatment costs. By offering a non‑antibiotic antimicrobial approach, Aseptuva helps health workers reduce dressing changes and combats antimicrobial resistance.